TrialThe Lancet. Infectious diseases2022

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.

Rajeka Lazarus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.